CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 108 enrolled
Drug / intervention
25mg Eplerenone +1 moredrug
Likely dose
25mg Eplerenonefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01990677
NCT01990677N/ACompleted
CompareCT.gov

Eplerenone for the Treatment of Central Serous Chorioretinopathy

Wills Eye·interventional·Posted Nov 21, 2013·Updated Nov 7, 2018

In Brief

A clinical study evaluating 25mg Eplerenone and Placebo for Central Serous Chorioretinopathy. Completed, enrolled 108 participants across 10 sites.

Detailed Summary

To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Serous Chorioretinopathy
CountriesUnited States
CollaboratorsMid Atlantic Retina

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 21, 2013
Enrollment StartOct 1, 2013
Primary CompletionMar 1, 2015
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.6 years ago

Interventions

25mg Eplerenonedrug

Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo

Placebodrug

Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.